Campaign merchandise is on display at a stall before a press briefing by the "Leave.EU" campaign group in central London on November 18, 2015. AFP PHOTO / LEON NEAL
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Fears of a British exit from the European Union are growing in a corner of London's Canary Wharf financial district – but this time it is pharmaceutical executives rather than bankers who are worried.With a full-time staff of more than 600, the EMA is the largest EU body in Britain – which is also home to the European Banking Authority – and has overseen pan-European drug approvals since 1995 from its headquarters tucked away among global banks.Many industry officials believe the EMA, as an EU agency governed by EU legislation, would relocate from London to a remaining member state.EMA officials said the agency would not speculate on the result of the British referendum or its potential consequences.The only other EU agency based in Britain is the European Banking Authority (EBA), established in 2011 and responsible for bank stress tests.
FOLLOW THIS ARTICLE